Jerrold Levy
Levy, Jerrold
Levy, Jerrold H.
VIAF ID: 85897844 (Personal)
Permalink: http://viaf.org/viaf/85897844
Preferred Forms
-
100 0 _
ââ¡aÂ
Jerrold Levyâ
-
100 1 _
ââ¡aÂ
Levy, Jerroldâ
-
100 1 _ ââ¡a Levy, Jerrold H.â
Â
Â
Â
Â
4xx's: Alternate Name Forms (4)
5xx's: Related Names (2)
- 510 2 _
ââ¡aÂ
Duke Universityâ
ââ¡bÂ
Medical Centerâ
ââ¡4Â
affiâ
ââ¡4Â
https://d-nb.info/standards/elementset/gnd#affiliationâ
ââ¡eÂ
Affiliationâ
- 551 _ _
ââ¡aÂ
Miami, Fla.â
ââ¡4Â
ortgâ
ââ¡4Â
https://d-nb.info/standards/elementset/gnd#placeOfBirthâ
Works
| Title | Sources |
|---|---|
| Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation |
|
| Goal-directed coagulation management in the perioperative period of cardiac surgery. |
|
| Guidelines for Perioperative Care in Cardiac Surgery: Enhanced Recovery After Surgery Society Recommendations |
|
| How I use fibrinogen replacement therapy in acquired bleeding |
|
| Hypercoagulability and COVID-19 associated hypoxemic respiratory failure: Mechanisms and emerging management paradigms |
|
| Idarucizumab for dabigatran overdose. |
|
| The Immunologic Effect of Early Intravenous Two and Four Gram Bolus Dosing of Tranexamic Acid Compared to Placebo in Patients With Severe Traumatic Bleeding (TAMPITI): A Randomized, Double-Blind, Placebo-Controlled, Single-Center Trial |
|
| The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review |
|
| Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P). |
|
| In vitro comparative study of hemostatic components in warfarin-treated and fibrinogen-deficient plasma |
|
| In vitro effects of recombinant activated factor VIIa (NovoSeven) on clopidogrel-induced platelet inhibition |
|
| In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry |
|
| Inflammatory response to cardiopulmonary bypass |
|
| The influence of hyperglycemia on neutrophil extracellular trap formation and endothelial glycocalyx damage in a mouse model of type 2 diabetes |
|
| The influence of various patient characteristics on D-dimer concentration in critically ill patients and its role as a prognostic indicator in the intensive care unit setting. |
|
| Is preoperative fibrinogen predictive for postoperative bleeding after coronary artery bypass grafting surgery? |
|
| Is the incidence of heparin-induced thrombocytopenia affected by the increased use of heparin for VTE prophylaxis? |
|
| Ischemic limb necrosis in septic shock: What is the role of high-dose vasopressor therapy? |
|
| Letter to the Editor: Managing Dabigatran-Related Bleeding |
|
| Low plasma fibrinogen levels with the Clauss method during anticoagulation with bivalirudin |
|
| Managing clotting: a North American perspective |
|
| More on Venous Thrombosis during Spaceflight |
|
| Multidisciplinary approach to the challenge of hemostasis |
|
| New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey |
|
| New oral anticoagulant-induced bleeding: clinical presentation and management |
|
| A novel method to assess platelet inhibition by eptifibatide with thrombelastograph |
|
| Patient Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference |
|
| Perioperative hemostatic management of patients treated with vitamin K antagonists |
|
| Perioperative management of patients receiving new oral anticoagulants: an international survey |
|
| A phase 2 prospective, randomized, double-blind trial comparing the effects of tranexamic acid with ecallantide on blood loss from high-risk cardiac surgery with cardiopulmonary bypass (CONSERV-2 Trial). |
|
| A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass. |
|
| The plasma supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: a pilot investigation |
|
| Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes |
|
| Position du GIHP sur les tests viscoélastiques : quelle place pour quelle indication en situation hémorragique ? |
|
| Preemptive use of bivalirudin for urgent on-pump coronary artery bypass grafting in patients with potential heparin-induced thrombocytopenia |
|
| Protection of the endothelial glycocalyx by antithrombin in an endotoxin-induced rat model of sepsis |
|
| Protocol adherence when managing massive bleeding following complex cardiac surgery: a study design pilot |
|
| Randomized evaluation of fibrinogen versus placebo in complex cardiovascular surgery: post hoc analysis and interpretation of phase III results |
|
| RE: The prothrombin time ratio is not a more effective marker for evaluating sepsis-induced coagulopathy than fibrin-related markers: Response to the Letter-to-the-Editor by Dr Wada |
|
| Recognition of heparin-induced thrombocytopenia and initiation of argatroban therapy after cardiothoracic surgery in the intensive care unit |
|
| Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy (SCARLET): an updated meta-analysis |
|
| Recombinant human transgenic antithrombin in cardiac surgery: a dose-finding study |
|
| Reducing thrombotic complications in the perioperative setting: an update on heparin-induced thrombocytopenia |
|
| Regulation of thrombin activity--pharmacologic and structural aspects |
|
| Repletion of factor XIII following cardiopulmonary bypass using a recombinant A-subunit homodimer. A preliminary report |
|
| Reversal agents for non-vitamin K antagonist oral anticoagulants |
|
| Safe application of a restrictive transfusion protocol in moderate-risk patients undergoing cardiac operations |
|
| Safety of Recombinant Activated Factor VII in Randomized Clinical Trials |
|
| Scientific and Standardization Committee Communication: Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19 |
|
| Sepsis-Induced Coagulopathy and Japanese Association for Acute Medicine DIC in Coagulopathic Patients with Decreased Antithrombin and Treated by Antithrombin. |
|
| Sepsis-induced disseminated intravascular coagulation, symmetrical peripheral gangrene, and amputations |
|
| Technology: Is There Sufficient Evidence to Change Practice in Point-of-Care Management of Coagulopathy? |
|
| Thrombin-activated thrombelastography for evaluation of thrombin interaction with thrombin inhibitors |
|
| Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin |
|
| Thromboinflammation and the hypercoagulability of COVID-19 |
|
| Thrombomodulin in disseminated intravascular coagulation and other critical conditions-a multi-faceted anticoagulant protein with therapeutic potential |
|
| Tissue plasminogen activator and thrombin generation measurements using the Thrombinoscope |
|
| Tranexamic Acid for Acute Hemorrhage: When Is Enough Evidence Enough? |
|
| Transfusion and hemostasis in cardiac surgery |
|
| Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). |
|
| Underlying disorders of disseminated intravascular coagulation: Communication from the ISTH SSC Subcommittees on Disseminated Intravascular Coagulation and Perioperative and Critical Care Thrombosis and Hemostasis |
|
| Understanding Potential Drug Side Effects: Can We Translate Molecular Mechanisms to Clinical Applications? |
|
| The unique characteristics of COVID-19 coagulopathy |
|
| Usefulness of Measuring Changes in SOFA Score for the Prediction of 28-Day Mortality in Patients With Sepsis-Associated Disseminated Intravascular Coagulation |
|
| Vascular injury in acute infections and COVID-19: everything old is new again |
|
| The vasodilatory effects of hydralazine, nicardipine, nitroglycerin, and fenoldopam in the human umbilical artery |
|
| Warfarin reversal with prothrombin complex concentrate confers better antifibrinolytic activity compared with recombinant activated factor VII. |
|
| What is blood and what is not? Caring for the Jehovah's Witness patient undergoing cardiac surgery |
|
| What is the evidence for platelet transfusion in perioperative settings? |
|
